BioAlliance Pharma : Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at August 31, 2013
06 September 2013 - 1:45AM
Business Wire
Regulatory News :
BioAlliance Pharma (Paris:BIO) :
Pursuant to article L.233-8 II of the Code de commerce (the
French Commercial Code) and article 223-16 of the Règlement
général de l’Autorité des Marchés Financiers (Regulation of the
French stock market authority):
Date Total number of outstanding shares Total number
of voting rights August 31, 2013 20, 656,675
Theoretical number of voting rights: 20, 656,675(including treasury
shares)
Number of real voting rights:
20,636,306(without treasury shares)
About BioAlliance PharmaDedicated to Specialty Pharma and
Orphan products in cancer treatment and in supportive care, with a
focus on drug resistance, BioAlliance conceives and develops
innovative products, for specialty markets especially in the
hospital setting and for orphan or rare diseases.Created in 1997
and introduced to the Euronext Paris market in 2005, BioAlliance
Pharma’s ambition is to become a leading player in these fields by
coupling innovation to patient needs. The company’s teams have the
key competencies required to identify, develop and register drugs
in Europe and USA; the products’ commercialization rights are
licensed to international commercial partners invested in the
hospital setting. In areas where medical needs are insufficiently
met, its targeted approaches help overcome drug resistance and
improve patient health & quality of life. For more information,
visit the BioAlliance Pharma web site at
www.bioalliancepharma.com.
BioAlliance Pharma SAJudith Gréciet, CEOTel.: +33 1 45 58
76 01Judith.greciet@bioalliancepharma.comorNicolas Fellmann,
CFOTel.: +33 1 45 58 71
00nicolas.fellmann@bioalliancepharma.comorALIZE RPCaroline
CarmagnolTel.: +33 6 64 18 99 59caroline@alizerp.com
Biotest (TG:BIO)
Historical Stock Chart
From Nov 2024 to Dec 2024
Biotest (TG:BIO)
Historical Stock Chart
From Dec 2023 to Dec 2024
Real-Time news about Biotest AG (Tradegate (DE)): 0 recent articles
More BioAlliance Pharma News Articles